Since new irAEs from PD1 inhibition can occur many months after starting treatment43, and onset of hypothyroidism post-PD-1 initiation can range from 0.7 weeks to 19 months5, there is the possibility that ongoing patient follow up will yield new toxicity events. This evidence concerns the gene PDCD1 and hypothyroidism.